Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-23 first-line axi-cel versus standard of care in high-risk LBCL
2022-501489-24-00Phase 3Authorised
- Sponsor
- Kite Pharma
- Start
- Aug 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma comparing Axicabtagene ciloleucel arm with Standard of care therapy arm (2 arms). Primary endpoint: Event-free survival. Planned start Aug 2023; status: authorised.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on 2022-501489-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501489-24-00.